Overview

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

Status:
Completed
Trial end date:
2010-06-02
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability of a single 1500 mg dose of famciclovir in 50 adolescents with recurrent herpes labialis. Eight of the 50 adolescents will also participate in the pharmacokinetics (PK) assessment of famciclovir single 1500 mg dose
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
2-Aminopurine
Famciclovir